Bilateral Thorathic Erector Spinae Plane Block in Laparoscopic Bariatic Surgeries

Launched by CAIRO UNIVERSITY · Feb 1, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a method to help manage pain for patients undergoing specific weight-loss surgeries called laparoscopic bariatric surgeries, which include sleeve gastrectomy and Roux-en-Y gastric bypass. The researchers want to find out if using a single injection (one-level) or two injections (two-level) of a special type of pain relief technique called the thoracic erector spinae plane block can provide better pain control during and after the surgery. They will also compare how much opioid medication (strong pain relievers) patients need in both groups.

To be eligible for this trial, participants should be adults aged 18 to 60 who are considered obese (with a body mass index between 35 and 50) and are scheduled for one of the mentioned surgeries. However, certain individuals may not qualify, such as those who refuse the procedure, have specific medical conditions, or have had prior surgeries that could complicate the trial. If you participate, you can expect to receive either the one-level or two-level block for pain relief, and the study will help determine which approach is more effective. The trial is not yet recruiting participants, so more information will be available as it progresses.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient age ranges 18 to 60 years old
• • Obese patients ; Body mass index(BMI) ≥ 35 - 50 kg/m2
• • American Society of Anesthesiologists (13) physical status classes II to III
• • Patients scheduled for laparoscopic bariatric surgery i.e. sleeve gastrectomy and/or Roux-en-Y gastric bypass (RYGB) surgeries
• Exclusion Criteria:
• • • Refusal of regional block
• • Patients with neurological, psychological disorders or those lacking cooperation.
• • Patients scheduled for concomitant laparoscopic cholecystectomy or paraumbilical hernia repair or those with history of previous bariatric surgery or obstructive sleep apnea.
• • Patients with anatomic abnormalities at site of injection, skin lesions or wounds at site of proposed needle insertion.
• • Patients with bleeding disorders defined as (INR \>1.4) and/ or (platelet count \<100,000/µL)
• • Patients with hepatic disease e.g. liver cell failure or hepatic malignancy or hepatic enlargement.
• • Patients who are allergic to amide local anesthetics